Il-11ra antibodies

Abstract

IL-11Ra antibodies are disclosed. Also disclosed are compositions comprising the IL-11Ra antibodies, and methods using the IL-11Ra antibodies.

1 - 35 . (canceled) 
     
     
         36 . An antibody or antigen binding fragment, optionally isolated, which is capable of binding to IL-11Rα, comprising a light chain variable region sequence and a heavy chain variable region sequence, wherein:
 the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO:7, and 
 the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16. 
 
     
     
         37 . The antibody or antigen binding fragment according to  claim 36 , wherein:
 the light chain variable region sequence has at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:7, and   the heavy chain variable region sequence has at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16.   
     
     
         38 . The antibody or antigen binding fragment according to  claim 36 , wherein the light chain variable region sequence comprises the following CDRs: 
       
         
           
                 
                 
                 
                 
               
                   i) 
                   LC-CDR1: 
                   QSISNN; 
                   (SEQ ID NO: 33) 
                 
                     
                 
                   ii) 
                   LC-CDR2: 
                   YAS; 
                   (SEQ ID NO: 34) 
                 
                   and 
                     
                     
                     
                 
                     
                 
                   iii) 
                   LC-CDR3: 
                   QQRYSWPLT; 
                   (SEQ ID NO: 35) 
                 
             
                
                
                
                
                
                
               
            
           
         
       
       and wherein the heavy chain variable region sequence comprises the following CDRs: 
       
         
           
                 
                 
                 
                 
               
                   iv) 
                   HC-CDR1: 
                   GYTFTNYW; 
                   (SEQ ID NO: 60) 
                 
                     
                 
                   v) 
                   HC-CDR2: 
                   IGPSDSKT; 
                   (SEQ ID NO: 61) 
                 
                     
                 
                   vi) 
                   HC-CDR3: 
                   ARGDYVLFTY. 
                   (SEQ ID NO: 62) 
                 
             
                
                
                
                
                
               
            
           
         
       
     
     
         39 . The antibody or antigen binding fragment according to  claim 36 , which is capable of inhibiting IL-11 trans signalling. 
     
     
         40 . The antibody or antigen binding fragment according to  claim 36 , wherein the antibody or antigen binding fragment is a humanised antibody or antigen binding fragment. 
     
     
         41 . The antibody or antigen binding fragment according  claim 36 , conjugated to a drug moiety or a detectable moiety. 
     
     
         42 . A method of treating fibrosis or a disease/disorder characterised by fibrosis, comprising administering an antibody or antigen binding fragment to a subject suffering from fibrosis or a disease/disorder characterised by fibrosis, wherein the antibody or antigen binding fragment is capable of binding to IL-11Rα, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
 the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO:7, and 
 the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16. 
 
     
     
         43 . The method according to  claim 42 , wherein:
 the light chain variable region sequence has at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:7, and   the heavy chain variable region sequence has at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16.   
     
     
         44 . The method according to  claim 42 , wherein the light chain variable region sequence comprises the following CDRs: 
       
         
           
                 
                 
                 
                 
               
                   i) 
                   LC-CDR1: 
                   QSISNN; 
                   (SEQ ID NO: 33) 
                 
                     
                 
                   ii) 
                   LC-CDR2: 
                   YAS; 
                   (SEQ ID NO: 34) 
                 
                   and 
                     
                     
                     
                 
                     
                 
                   iii) 
                   LC-CDR3: 
                   QQRYSWPLT; 
                   (SEQ ID NO: 35) 
                 
             
                
                
                
                
                
                
               
            
           
         
       
       and wherein the heavy chain variable region sequence comprises the following CDRs: 
       
         
           
                 
                 
                 
                 
               
                   iv) 
                   HC-CDR1: 
                   GYTFTNYW; 
                   (SEQ ID NO: 60) 
                 
                     
                 
                   v) 
                   HC-CDR2: 
                   IGPSDSKT; 
                   (SEQ ID NO: 61) 
                 
                     
                 
                   vi) 
                   HC-CDR3: 
                   ARGDYVLFTY. 
                   (SEQ ID NO: 62) 
                 
             
                
                
                
                
                
               
            
           
         
       
     
     
         45 . The method according to  claim 42 , wherein the antibody or antigen binding fragment is capable of inhibiting IL-11 trans signalling. 
     
     
         46 . The method according to  claim 42 , wherein the antibody or antigen binding fragment is a humanised antibody or antigen binding fragment. 
     
     
         47 . The method according to  claim 42 , wherein the antibody or antigen binding fragment is conjugated to a drug moiety or a detectable moiety. 
     
     
         48 . A method of treating cancer, comprising administering an antibody or antigen binding fragment to a subject suffering from cancer, wherein the antibody or antigen binding fragment is capable of binding to IL-11Rα, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
 the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO:7, and 
 the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16. 
 
     
     
         49 . The method according to  claim 48 , wherein:
 the light chain variable region sequence has at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:7, and   the heavy chain variable region sequence has at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16.   
     
     
         50 . The method according to  claim 48 , wherein the light chain variable region sequence comprises the following CDRs: 
       
         
           
                 
                 
                 
                 
               
                   i) 
                   LC-CDR1: 
                   QSISNN; 
                   (SEQ ID NO: 33) 
                 
                     
                 
                   ii) 
                   LC-CDR2: 
                   YAS; 
                   (SEQ ID NO: 34) 
                 
                   and 
                     
                     
                     
                 
                     
                 
                   iii) 
                   LC-CDR3: 
                   QQRYSWPLT; 
                   (SEQ ID NO: 35) 
                 
             
                
                
                
                
                
                
               
            
           
         
       
       and wherein the heavy chain variable region sequence comprises the following CDRs: 
       
         
           
                 
                 
                 
                 
               
                   iv) 
                   HC-CDR1: 
                   GYTFTNYW; 
                   (SEQ ID NO: 60) 
                 
                     
                 
                   v) 
                   HC-CDR2: 
                   IGPSDSKT; 
                   (SEQ ID NO: 61) 
                 
                     
                 
                   vi) 
                   HC-CDR3: 
                   ARGDYVLFTY. 
                   (SEQ ID NO: 62) 
                 
             
                
                
                
                
                
               
            
           
         
       
     
     
         51 . The method according to  claim 48 , wherein the antibody or antigen binding fragment is capable of inhibiting IL-11 trans signalling. 
     
     
         52 . The method according to  claim 48 , wherein the antibody or antigen binding fragment is a humanised antibody or antigen binding fragment. 
     
     
         53 . The method according to  claim 48 , wherein the antibody or antigen binding fragment is conjugated to a drug moiety or a detectable moiety.